Global osteoporosis market report sees strong showing in China
The global market for drugs to treat osteoporosis was estimated to be worth $7.3 billion in 2010 and expected to reach $11.4 billion in 2015, increasing at a compound annual growth rate (CAGR) of 9.2% over the period 2010 to 2015, according to a new report published by Transparency Market.
The bisphosphonate segment accounted for the largest share at 62.0% of weight management market in 2010. The China osteoporosis market will be reach a value of $2.5 billion in 2015, the report predicts.
In the overall bisphosphonates class, ibandronate (Bonviva/Boniva from Roche) and zoledronate (Aclasta/Zometa from Novartis) accounted for healthy market shares and showed an average sales growth rate of about of 20% in the past two years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze